Inorg. Chem. **2006**, 45, 7581−7583

Active-Site Models of Bacterial Nitric Oxide Reductase Featuring Tris-Histidyl and Glutamic Acid Mimics: Influence of a Carboxylate Ligand on Fe_B Binding and the Heme Fe/Fe_B Redox Potential

James P. Collman,* Yi-Long Yan, Jianping Lei, and Peter H. Dinolfo

*Department of Chemistry, Stanford Uni*V*ersity, Stanford, California 94305-5080*

Received May 25, 2006

Active-site models of bacterial nitric oxide reductase (NOR) featuring a heme Fe and a trisimidazole- and glutaric acid-bound non-heme Fe (Fe_B) have been synthesized. These models closely replicate the proposed active site of native NORs. Examination of these models shows that the glutamic acid mimic is required for both Fe_B retention in the distal binding site and proper modulation of the redox potentials of both the heme and non-heme Fe's.

Biological denitrification is a four-step process that reduces nitrate to dinitrogen (eq 1). This process not only is important for bacteria in anaerobic energy generation but also represents a major pathway by which vast amounts of fixed nitrogen are returned to the atmosphere. $1-3$ Bacterial nitric oxide reductase (NOR) is a membrane-bound enzyme that catalyzes the third step of denitrification: the two-electron reduction of nitric oxide to nitrous oxide (eq 2 and Figure 1). NORs are members of the heme-copper oxidase superfamily and are believed to be ancestral relatives of cytochrome *c* oxidase (C*c*O).

$$
NO_3^- \to NO_2^- \to NO \to N_2O \to N_2 \tag{1}
$$

$$
2NO + 2e^- + 2H^+ \rightarrow N_2O + H_2O \tag{2}
$$

The active sites of both C*c*O and NOR are bimetallic with a proximal imidazole-ligated heme Fe and a distal tris-Hiscoordinated metal ion. In CcO, the distal ion is copper (Cu_B) , while in NOR, it is a non-heme Fe (Fe_B) (Figure 1).¹⁻³ While the distal metal binding sites of C*c*O and NOR are very similar, there are a few differences between them that likely account for the selectivity between Cu and Fe and thus the preferred reactivity for O₂ and NO, respectively. In CcO, a redox-active phenol group from a Tyr residue is post-

-
- (2) Zumft, W. G. *Microbiol. Mol. Biol. Re*V*.* **¹⁹⁹⁷**, *⁶¹*, 533-616. (3) Hendriks, J.; Warne, A.; Gohlke, U.; Haltia, T.; Ludovici, C.; Lubben, M.; Saraste, M. *Biochemistry* **¹⁹⁹⁸**, *³⁷*, 13102-13109.

10.1021/ic0609150 CCC: \$33.50 © 2006 American Chemical Society **Inorganic Chemistry,** Vol. 45, No. 19, 2006 **7581** Published on Web 08/25/2006

Figure 1. Schematic representation of the bimetallic active sites of bacterial NOR and CcO.

translationally coupled to one of the Cu_B ligating imidazoles. In NOR, this phenol group is absent, but a conserved glutamic acid residue is located near the active site and is reported to be essential for normal levels of NOR activity.4 It has been suggested that this glutamic acid provides an additional ligand for Fe_B, which prefers octahedral coordination. It has been proposed that this glutamic acid residue increases the selective binding of the distal non-heme Fe_B (over that of Cu), regulates the charge at the active site, and possibly mediates the uptake of protons during catalytic turnover of NO.4,5

The development of biomimetic models to investigate the structural-functional relationships of native metalloenzymes has proven to be a successful strategy. $6-11$ Simulation and variation of synthetic models provide insight into the coordination environments, spectroscopic properties, and catalytic mechanisms of metalloenzymes. Such detailed information and systematic variations are difficult to obtain

- (4) Butland, G.; Spiro, S.; Watmough, N. J.; Richardson, D. J. *J. Bacteriol.* **²⁰⁰¹**, *¹⁸³*, 189-199.
- (5) Gronberg, K. L. C.; Roldan, M. D.; Prior, L.; Butland, G.; Cheesman, M. R.; Richardson, D. J.; Spiro, S.; Thomson, A. J.; Watmough, N. J. *Biochemistry* **¹⁹⁹⁹**, *³⁸*, 13780-13786.
- (6) Holm, R. H.; Solomon, E. I. *Chem. Re*V*.* **²⁰⁰⁴**, *¹⁰⁴*, 347-348.
- (7) Collman, J. P.; Boulatov, R.; Sunderland, C. J.; Fu, L. *Chem. Re*V*.* **²⁰⁰⁴**, *¹⁰⁴*, 561-588.
- (8) Solomon, E. I.; Szilagyi, R. K.; George, S. D.; Basumallick, L. *Chem.*
- Rao, P. V.; Holm, R. H. Chem. Rev. 2004, 104, 527-559. (9) Rao, P. V.; Holm, R. H. *Chem. Re*V*.* **²⁰⁰⁴**, *¹⁰⁴*, 527-559.
- (10) Tshuva, E. Y.; Lippard, S. J. *Chem. Re*V*.* **²⁰⁰⁴**, *¹⁰⁴*, 987-1011.
- (11) Kim, E.; Chufan, E. E.; Kamaraj, K.; Karlin, K. D. *Chem. Re*V*.* **²⁰⁰⁴**, *¹⁰⁴*, 1077-1133.

^{*} To whom correspondence should be addressed. E-mail: jpc@ stanford.edu.

⁽¹⁾ Wasser, I. M.; de Vries, S.; Moenne-Loccoz, P.; Schroder, I.; Karlin, K. D. *Chem. Rev.* 2002, 102, 1201-1234.
(2) Zumft, W. G. *Microbiol. Mol. Biol. Rev.* 1997, 61, 533-616.

Chart 1

Chart 2

from wild-type enzymes or their mutants because of their restricted availability and difficulty in mutagenesis. To date, only a few synthetic models have been reported that imitate the active site of NOR; none of these contain a mimic for the conserved glutamic acid moiety. $1,12,13$ To draw accurate conclusions about structural-functional relationships from biomimetic models, it is important that these synthetic models reproduce all of the key structural features of the native enzyme.

In this paper, we report a new synthetic NOR active-site model (**2a**) featuring a heme Fe and a trisimidazole- and glutaric acid-bound non-heme Fe. This model most closely replicates the active site of native NOR. Examination of this model shows that the glutamic acid mimic is required for both Fe_B retention in the distal binding site and proper modulation of the redox potentials of both the heme and nonheme Fe's.

NOR model ligands **¹** (**1a**-**c**) bearing trisimidazole pickets (Chart 1) were prepared following a scheme recently developed in our laboratory.¹⁴ Variation at the R group from glutaric acid (**1a**) to glutaric ester (**1b**) and a hexyl group (**1c**) provides opportunities to investigate the impact of the glutaric acid residue on non-heme Fe binding and the electrochemical properties of the Fe₂ active site. $1a - c$ were fully characterized by ${}^{1}H$ and ${}^{13}C$ NMR and high-resolution mass spectrometry (HRMS) analysis.^{14,15} While this generation of NOR models does not contain a proximal imidazole for coordination to the heme Fe, it has been reported that in

⁽¹³⁾ Wasser, I. M.; Martens, C. F.; Verani, C. N.; Rentschler, E.; Huang, H. W.; Moenne-Loccoz, P.; Zakharov, L. N.; Rheingold, A. L.; Karlin, K. D. *Inorg. Chem.* **²⁰⁰⁴**, *⁴³*, 651-662.

Figure 2. CVs of **2a**/**3a** (panel a) and **2b**/**3b** (panel b) adsorbed on an EPG electrode at a coverage of 2.5 nmol/cm2. Scans were taken in a deoxygenated phosphate buffer (pH = 7.0) at a scan rate of 10 mV/s.

the native enzyme the imidazole disassociates from the heme Fe after binding of NO.16,17

Reaction of $1a-c$ under a N_2 atmosphere with excess $FeCl₂$ and $K₂CO₃$ in tetrahydrofuran provides Fe₂ models **2a**-**c**, respectively (Chart 2).15 The identities of the paramagnetic Fe₂ complexes $2a-c$ were confirmed by mass analysis (low-resolution mass spectrometry, LRMS, and HRMS).15 LRMS and HRMS data for **2a** reveal that only a single Cl ion is present in the structure and with glutaric carboxylate, accounting for the charge balance of the nonheme Fe in the distal site. In contrast, LRMS and HRMS data reveal that two Cl ions are present in **2b** and **2c**. 15

The coordination of the non-heme Fe by glutaric carboxylate is consistent with the following observations: when a CH_2Cl_2 solution of **2a**, **2b**, or **2c** is washed thoroughly with deoxygenated water under N_2 , 2b and 2c lost their non-heme Fe to give the corresponding mono-heme Fe complex (**3b** and **3c**). In contrast, the non-heme Fe in **2a** survives such an aqueous treatment. Stirring a CH₂Cl₂ solution of 2a with an excess amount of saturated Na₂EDTA (a strong Fe²⁺ chelator) in water for 5 h under N_2 successfully removes the non-heme Fe of **2a**, forming **3a**. The identities of **3a**-**^c** were confirmed by LRMS and HRMS and further supported by electrochemical analysis (Figure 2).¹⁵ Compared with those of **2a**-**c**, the redox couples corresponding to the nonheme Fe disappeared on the cyclic voltammograms (CVs) of compounds **3a**-**c**. These results suggest that the non-heme Fe is only weakly bound by the tris-imidazole pocket of **2b** and **2c**, while coordination of the non-heme Fe by the three imidazoles and glutaric carboxylate significantly increases the stability of **2a** in aqueous media. Thus, the conserved glutamic acid moiety present at the NOR active site may be required for retention of Fe_B because native NOR needs to function in an aqueous biological system.

The exact molecular mechanism of NO reduction by NOR is still the subject of much debate. To date, two general schemes have been proposed: the "trans" mechanism involves the binding of a molecule of NO to both heme b_3 and Fe_B, while the "cis" method suggests that two molecules of NO bind to Fe_B solely. Spectroscopic examination of

⁽¹²⁾ Wasser, I. M.; Huang, H. W.; Moenne-Loccoz, P.; Karlin, K. D. *J. Am. Chem. Soc.* **²⁰⁰⁵**, *¹²⁷*, 3310-3320.

⁽¹⁶⁾ Brudvig, G. W.; Stevens, T. H.; Chan, S. I. *Biochemistry* **1980**, *19*, 5275–5285.
Moenne-Loc

⁽¹⁷⁾ Moenne-Loccoz, P.; de Vries, S. *J. Am. Chem. Soc.* **¹⁹⁹⁸**, *¹²⁰*, 5147- 5152.

Figure 3. pH dependence of the $Fe^{III}Fe_{B}^{III}/Fe^{II}Fe_{B}^{II}$ potential (E°) for 2a at an EPG electrode. Scan rate $= 10$ mV/s.

single-turnover steps, using time-resolved Raman, electron paramagnetic resonance, and optical absorption spectroscopies, typically starts with the fully reduced enzyme (heme b_3 Fe^{II}/Fe_B^{II}). Alternatively, it has been suggested that the mixed-valent state of the active site (heme b_3 Fe^{III}/Fe_B^{II}) may represent the active form of the enzyme.5,18 Mediated redox potentiometry experiments on NOR isolated from *P. denitrificans* reveal that the midpoint potential of the heme b_3 (E_m = +60 mV vs normal hydrogen electrode, NHE) is unexpectedly lower than that of C*c*O.5 In addition, the midpoint potential of Fe_B is approximately 260 mV positive of that of heme *b*3. The large potential difference between heme b_3 and Fe_B, combined with the apparent low potential of heme *b*3, suggests that the enzyme may not achieve the fully reduced state (heme b_3 Fe^{II}/Fe^{II} _B) under physiological conditions. This would avoid the formation of a stable heme Fe^{II}-NO complex, a potential thermodynamic trap in the catalytic cycle.

The energetic cost of placing a charged carboxylate residue in a lipid layer supports the proposal that the glutamic acid residue ligates Fe_B, regulates the charge, and mediates the redox potential of the $Fe₂$ center active site.^{4,5} Indeed, replacement of the glutamic acid residue closest to the active site with alanine results in a -120 mV negative shift in the Fe_B midpoint potential from to $+200$ mV vs NHE in conjunction with a decrease in the NOR activity.4

Figure 2 shows the CVs of **2a**/**3a** and **2b**/**3b** adsorbed on an edge-plane graphite (EPG) electrode in a deoxygenated $pH = 7$ buffer.¹⁹ All of the Fe₂ complexes show a single reduction wave, corresponding to the simultaneous reduction of both the heme Fe and FeB. **2b** and **2c**, without a $carboxylate available to ligate Fe_B, show the same peak$ oxidation potentials (E_{pa}) for the non-heme Fe_B and heme Fe at +115 mV vs NHE (Figure 2, panel b). In contrast, the CV for $2a$ shows two distinct oxidation waves at $+40$ and

-80 mV vs NHE, corresponding to the non-heme Fe and heme Fe, respectively (Figure 2, panel a).

The pH dependence of the $Fe^{III}Fe_{B}^{III}/Fe^{II}Fe_{B}^{II}$ reduction potential (*E*°′) for **2a** was also examined (Figure 3) and found to be -58 mV/pH in the range of pH $= 6-10^{20}$ This represents a two-electron, two-proton reaction^{21,22} for the reduction of **2a** and is consistent with the reduction of a μ -oxo-bridged active site (heme Fe^{III} -O- Fe^{III}). The heme Fe^{III} -O- Fe^{III} state (or protonated form heme heme $Fe^{III} - O - Fe_B^{III}$ state (or protonated form, heme
 $Fe^{III} - O(H) - Fe_B^{III}$) is believed to be the resting (oxidized) $[Fe^{III}-O(H)-Fe_B^{III}]$ is believed to be the resting (oxidized)
state of NOR and possibly the final step in the catalytic cycle state of NOR and possibly the final step in the catalytic cycle of NOR.1,17,18,23-²⁸

In summary, we have developed several models that closely replicate the bimetallic active site of bacterial NOR. These complexes reproduce the key structural features of the catalytic $Fe₂$ center of native NOR and represent the best available synthetic NOR active-site models examined to date. The presence of a glutamic acid mimic significantly increases the stability of Fe_B binding in the distal site while modulating the redox potentials of both the heme Fe and Fe_B centers. Further investigation of the single-turnover reactions of NO and $O₂$ with these models, as well as steady-state electrocatalytic studies of NO reduction, is currently in progress. Such an investigation should provide meaningful information regarding the mechanism of NO reduction to N_2O by bacterial NOR.

Acknowledgment. This material is based upon work supported by NIH Grants GM-69568-01A1 and GM-017880- 35.

Supporting Information Available: ¹H and ¹³C NMR spectral data of **1a**-**c**, HRMS spectral data of **1a**-**c**, **2a**-**c**, and **3a**-**c**, and CVs of **2a**-**^c** and **3a**-**c**. This material is available free of charge via the Internet at http://pubs.acs.org.

IC0609150

- (20) Under more acid conditions ($pH \le 6$), the non-heme Fe in **2a** is rapidly lost, most likely because of protonation of glutaric carboxylate.
- (21) Bard, A. J.; Faulkner, L. R. *Electrochemical Methods: Fundamentals and Applications*, 2nd ed.; John Wiley & Sons: New York, 2001.
- (22) Boulatov, R.; Collman, J. P.; Shiryaeva, I. M.; Sunderland, C. J. *J. Am. Chem. Soc.* **²⁰⁰²**, *¹²⁴*, 11923-11935.
- (23) Moenne-Loccoz, P.; Richter, O. M. H.; Huang, H. W.; Wasser, I. M.; Ghiladi, R. A.; Karlin, K. D.; de Vries, S. *J. Am. Chem. Soc.* **2000**, *¹²²*, 9344-9345.
- (24) Kurose, S.; Sakurai, N.; Sakurai, T. *J. Inorg. Biochem.* **²⁰⁰¹**, *⁸³*, 281- 286.
- (25) Field, S. J.; Prior, L.; Roldan, M. D.; Cheesman, M. R.; Thomson, A. J.; Spiro, S.; Butt, J. N.; Watmough, N. J.; Richardson, D. J. *J. Biol. Chem.* **²⁰⁰²**, *²⁷⁷*, 20146-20150.
- (26) Pinakoulaki, E.; Gemeinhardt, S.; Saraste, M.; Varotsis, C. *J. Biol. Chem.* **²⁰⁰²**, *²⁷⁷*, 23407-23413.
- (27) Kumita, H.; Matsuura, K.; Hino, T.; Takahashi, S.; Hori, H.; Fukumori, Y.; Morishima, I.; Shiro, Y. *J. Biol. Chem.* **²⁰⁰⁴**, *²⁷⁹*, 55247-55254.
- (28) Sakurai, T.; Nakashima, S.; Kataoka, K.; Seo, D.; Sakurai, N. *Biochem. Biophys. Res. Commun.* **²⁰⁰⁵**, *³³³*, 483-487.

⁽¹⁸⁾ Groenberg, K. L. C.; Watmough, N. J.; Thomson, A. J.; Richardson, D. J.; Field, S. J. *J. Biol. Chem.* **²⁰⁰⁴**, *²⁷⁹*, 17120-17125.

⁽¹⁹⁾ The CV of **2c**/**3c** is provided in the Supporting Information.